Join the STOP-PC Pancreatic Cancer Study

Oncotelic Therapeutics, a company with a history of evolving its focus from OXiGENE, Inc. to Mateon Therapeutics, and finally to its current name, is dedicated to enhancing cancer treatment outcomes. With a special interest in rare pediatric cancers, Oncotelic has received a rare pediatric designation for Diffuse Intrinsic Pontine Glioma through its joint venture, GMP Biotechnology Limited. The company has also ventured into AI technology with the acquisition of PointR Data Inc. and has plans to develop AL-101 for various conditions, including Parkinson's Disease and erectile dysfunction.

The company is currently conducting the STOP-PC trial, a Phase 2b/3 study that combines the TGF-β2 targeting antisense oligonucleotide OT-101 with mFOLFIRINOX chemotherapy for patients with advanced pancreatic cancer. TGF-β is a protein that can suppress the immune response in cancerous tissues, aiding tumor growth. OT-101 is an innovative RNA therapeutic that aims to counteract the immunosuppressive effects of TGF-β2, potentially slowing disease progression. The drug has shown significant single-agent activity, with improved overall survival rates that increase with dosage.

The trial is designed to evaluate the effectiveness of OT-101 in combination with mFOLFIRINOX as a second-line therapy for patients whose cancer has worsened. Dr. Vuong Trieu, CEO of Oncotelic, is optimistic about the trial's potential to significantly improve survival rates for pancreatic cancer patients.

Cromos Pharma, an international contract research organization (CRO) founded in 2004, is supporting Oncotelic in its clinical research efforts. With a strong track record of over 300 completed clinical trials, Cromos offers a wide range of services across various therapeutic areas, including oncology. The company is known for its commitment to excellence and its ability to expedite drug development while maintaining high-quality standards. Cromos Pharma operates globally, with a presence in numerous countries across Europe and Asia.

Oncotelic's mission is to leverage its expertise in oncology drug development to improve the survival and quality of life for cancer patients. The company is also focused on developing innovative treatments for a variety of conditions with significant patient populations in need.